Evidence map›Paper›PMID 35174566›Full record

SynthesisClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2022

Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis.

David Charles, Jemma Shanley, Sasha-Nicole Temple, Anna Rattu, Ekaterina Khaleva, Graham Roberts

Open access · hybridAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 5 pooled it
11.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 5 syntheses or guidelines pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2022
    Pooled it
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Observational
  18. Review
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

David CharlesAcademic Clinical Medicine, Southampton General Hospital, Southampton, UK.
Jemma ShanleyChild Health, Southampton General Hospital, Southampton, UK.
Sasha-Nicole TempleClinical Medicine, Royal London Hospital, London, UK.
Anna RattuClinical and Experimental Sciences and Human Development, Faculty of Medicine, University of Southampton, Southampton, UK.
Ekaterina KhalevaClinical and Experimental Sciences and Human Development, Faculty of Medicine, University of Southampton, Southampton, UK.
Graham RobertsClinical and Experimental Sciences and Human Development, University of Southampton, Southampton, UK.ORCID 0000-0003-2252-1248
University of Southampton · GBSouthampton General Hospital · GBRoyal London Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSevere asthma is a major cause of morbidity. Some patients may benefit from biological therapies. Most evaluations of these treatments are derived from randomized controlled trials (RCTs), but few patients are eligible for these trials. Studies involving more diverse groups of participants exist, but there is a lack of precise pooled estimates.

objectiveThis systematic review aims to evaluate the real-world efficacy of recently and nearly licensed biological therapies for severe asthma to assess the generalizability of the RCT data.

methodsClinical outcomes including exacerbation rate, oral corticosteroid usage, forced expiratory volume in 1 second (FEV

resultsA total of 21 studies examining biologicals in real-world settings were identified; they mostly focused on benralizumab and mepolizumab. The introduction of biologicals reduced the annualzsed exacerbation rate significantly by -3.79 (95% confidence interval [CI] -4.53, -3.04), -3.17 (95% CI -3.74, -2.59) and -6.72 (95% CI -8.47, -4.97) with benralizumab, mepolizumab and reslizumab, respectively. Likewise, improvements were observed in FEV

conclusionsThese data demonstrate that anti-IL5 biologicals may improve the clinical outcomes of patients with severe asthma in a clinic environment with similar effect sizes to RCTs. The data were mainly retrospective and unadjusted, so estimated effect sizes may not be reliable. More data are needed to acquire accurate effect estimates in different subpopulations of patients.

Indexed as

Anti-Asthmatic AgentsAsthmaBiological ProductsAntibodies, Monoclonal, HumanizedHumansRandomized Controlled Trials as TopicAnti-Asthmatic AgentsAntibodies, Monoclonal, HumanizedbenralizumabBiological Productsdupilumabmepolizumabreslizumabasthmaasthma controlbenralizumabdupilumabexacerbationsFeNOFEV1mepolizumabreal-world studiesreslizumab

Identifiers

PMID35174566
PMCPMC9311192
OpenAlexW4213350887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.